Blog

Safety, Pharmacokinetics and Pharmacodynamics of Sofnobrutinib, a Novel Con-Covalent BTK Inhibitor, in Healthy Subjects: First-in-Human Phase I Study

An article by Clinical & Translational Science on the American Society for Clinical Pharmacology & Therapeutics.

Share this article

Other recent articles

BioTech News & Life Sciences Article – Drug Development Plan – English Version

BiotechNEWS & Life Sciences Article - Drug Development Plan - Dutch Version

1 2 Next »

Ready to see how Venn Life Sciences could speed up your drug development program?
Get in touch.